# Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With Non Small Cell Lung Cancer (NSCLC)

> **NCT02419170** · EARLY_PHASE1 · WITHDRAWN · sponsor: **Washington University School of Medicine**

## Conditions studied

- Carcinoma, Non-Small-Cell-Lung
- Non-Small Cell Lung Cancer
- Nonsmall Cell Lung Cancer

## Interventions

- **PROCEDURE:** Standard of care surgery
- **PROCEDURE:** Apheresis
- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** Personalized mature dendritic cell vaccine

## Key facts

- **NCT ID:** NCT02419170
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-07
- **Primary completion:** 2019-10
- **Final completion:** 2023-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Investigator who manufactured the vaccine left the university.
- **Last updated:** 2016-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02419170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02419170, "Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With Non Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02419170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*